It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Safe and effective brain tumor surgery aims to remove tumor tissue, not non-tumoral brain. This is a challenge since tumor cells are often not visually distinguishable from peritumoral brain during surgery. To address this, we conducted a multicenter study testing whether the Sentry System could distinguish the three most common types of brain tumors from brain tissue in a label-free manner. The Sentry System is a new real time, in situ brain tumor detection device that merges Raman spectroscopy with machine learning tissue classifiers. Nine hundred and seventy-six in situ spectroscopy measurements and colocalized tissue specimens were acquired from 67 patients undergoing surgery for glioblastoma, brain metastases, or meningioma to assess tumor classification. The device achieved diagnostic accuracies of 91% for glioblastoma, 97% for brain metastases, and 96% for meningiomas. These data show that the Sentry System discriminated tumor containing tissue from non-tumoral brain in real time and prior to resection.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Polytechnique Montréal, Montreal, Canada (GRID:grid.183158.6) (ISNI:0000 0004 0435 3292); Centre de Recherche du Centre Hospitalier de l’Université de Montréal, Montreal, Canada (GRID:grid.410559.c) (ISNI:0000 0001 0743 2111)
2 Montreal Neurological Institute-Hospital, McGill University, Division of Neuropathology, Department of Pathology, Montreal, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649)
3 Reveal Surgical, Montreal, Canada (GRID:grid.14709.3b)
4 Mount Sinai Hospital, New York, USA (GRID:grid.416167.3) (ISNI:0000 0004 0442 1996)
5 Polytechnique Montréal, Montreal, Canada (GRID:grid.183158.6) (ISNI:0000 0004 0435 3292); Centre de Recherche du Centre Hospitalier de l’Université de Montréal, Montreal, Canada (GRID:grid.410559.c) (ISNI:0000 0001 0743 2111); Institut du Cancer de Montréal, Montreal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357)
6 Mount Sinai Hospital, New York, USA (GRID:grid.416167.3) (ISNI:0000 0004 0442 1996); University of Pittsburgh Medical Center, Pittsburgh, USA (GRID:grid.412689.0) (ISNI:0000 0001 0650 7433)
7 Montreal Neurological Institute-Hospital, McGill University, Montreal, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649)